FDA Considers Additive to Detox Pig Feed from Sneaky Zearalenone
Published Date: 9/3/2025
Proposed Rule
Summary
Biomin GmbH asked the FDA to approve a new food additive that helps break down a harmful toxin called zearalenone in pig feed. This change aims to keep pigs healthier by reducing this toxin safely. If approved, farmers could start using this additive soon, making pig food safer without extra costs.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Proposal to Allow Enzyme in Swine Feed
The FDA received a petition to allow the enzyme zearalenone hydrolase to be added to swine feed at no less than 10 U/kg of complete feed (U = the five-fold enzymatic activity that hydrolyzes 1 µmol zearalenone per minute in a solution of 5 mg/L zearalenone). If approved, feed makers and pig farmers could legally use this enzyme in pig feed at that specified dose.
Reduces Harmful Zearalenone in Pigs
The petition says the additive helps break down the harmful toxin zearalenone in pig feed and aims to keep pigs healthier by reducing that toxin safely. This change is intended to improve animal health on farms by lowering zearalenone exposure in swine.
No Extra Feed Cost If Approved
The document states that if approved, farmers could start using the additive soon and that it would make pig feed safer without extra costs. That means, according to the petition summary, farmers would not face added feed costs when adopting the enzyme.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-16836, State Approving Agency Jurisdiction Rule
The VA is updating rules to clearly explain what counts as independent study, distance learning, and resident learning, plus adding a new term called standard curriculum. This helps State Approving Agencies know exactly which courses they oversee, especially for online classes. These changes affect schools and veterans using education benefits and aim to make things clearer without extra costs or delays.
Next: 2025-16866, Disclosure of Returns and Return Information in Connection With Written Contracts or Agreements for the Acquisition of Property or Services for Tax Administration Purposes; Withdrawal
The government decided to cancel a plan that would have let the State Department share tax info with its contractors to help with passport issues tied to unpaid taxes. This change means no new rules or costs will happen, and people dealing with passport problems won’t see any new info-sharing. Basically, the plan was dropped because it wasn’t needed after all.